Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
07/2006
07/27/2006US20060165758 Blunting the postprandial glycemic response by instant feed containing proteins, fats, carbohydrates, neutral soluble dietary fiber (guar gum, pectin, locust bean gum, methylcellulose), and hydrolyzed starch; diabetes
07/27/2006US20060165757 5-hydroxysapogenin derivatives with anti-dementia activity
07/27/2006US20060165756 Method for weight management
07/27/2006US20060165735 Stable emulsions of oils in aqueous solutions and methods for producing same
07/27/2006US20060165733 Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol
07/27/2006US20060165726 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like
07/27/2006US20060165706 Antibodies against CTLA4 and uses therefor
07/27/2006US20060165701 Agents for the diagnosis and treatment of tumors that expose alerted proteins on the cell surface
07/27/2006US20060165607 Carbon dioxide external preparation and material for formation of carbon dioxide external preparation
07/27/2006US20060165606 Perforated microstructure; efficiently depositing compound at site of action; minimizing toxic side effects, lowering dosing requirements
07/27/2006US20060165594 Preparation of m(co)3-complexes by solid phase techniques via metal assisted cleavage from the solid support
07/27/2006US20060165592 Nk cell receptor conjugates for treating malignancies
07/27/2006US20060165591 Metal complex-containing pharmaceutical agents
07/27/2006US20060163526 high pressure homogenization; high throughput screening
07/27/2006DE19853729B4 Verwendung einer im Magen-Darm-Kanal eines Tieres zerfallenden, knetbaren Trägerzusammensetzung Use of a gastro-intestinal tract of an animal decaying, malleable carrier composition
07/27/2006DE102005003010A1 Copolymere für kosmetische Mittel, hergestellt in Gegenwart polyfunktioneller Regler Copolymers for cosmetics, in the presence of polyfunctional regulator
07/27/2006DE102005002711A1 Herstellung und Verwendung von Monoglyceriden Preparation and use of monoglycerides
07/27/2006DE10025671B4 Emulgatoren Emulsifiers
07/27/2006CA2604394A1 Hyaluronic acid derivative and neural stem cells for sci and pnt regeneration
07/27/2006CA2595909A1 Method of conjugating aminothiol containing molecules to vehicles
07/27/2006CA2595902A1 Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
07/27/2006CA2595461A1 Method for producing albumin conjugates containing gyrase inhibitors
07/27/2006CA2595063A1 Emulsified composition for dilution and cancer vaccine composition
07/27/2006CA2593359A1 Direct compression formulation and process
07/27/2006CA2593112A1 Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
07/26/2006EP1683871A2 Nucleic acid ligands and methods for producing the same
07/26/2006EP1683812A1 Crosslinked polysaccharide microparticles and method for their preparation
07/26/2006EP1683781A2 Polyglycerine partial esters of polyricinoleic acid and polycarbonxylic acids and their use in the preparation of emulsions and dispersions
07/26/2006EP1683560A1 Radial spherical crystallization product, process for producing the same and dry powder preparation containing the crystallization product
07/26/2006EP1683529A1 Inclusion compound of porphyrin metal complex and albumin
07/26/2006EP1683528A1 Polysaccharide-containing composition and tear film stabilizing ophthalmic solution
07/26/2006EP1683526A1 Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac
07/26/2006EP1683525A1 Sustained-release phenylalanine derivative preparation for oral administration
07/26/2006EP1683524A1 Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative
07/26/2006EP1683520A2 Water-soluble paclitaxel produgs
07/26/2006EP1683518A1 Pharmaceutical formulation of a stable formoterol-containing propylene glycol solution for use in inhalation therapy and method of preparing it
07/26/2006EP1683517A1 Methods for the production of protein particles useful for delivery of pharmacological agents
07/26/2006EP1682660A2 RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
07/26/2006EP1682584A1 A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
07/26/2006EP1682583A1 Protein complex using immunoglobulin fragment and method for the preparation thereof
07/26/2006EP1682582A1 Method for the mass production of immunoglobulin constant region
07/26/2006EP1682581A1 Igg fc fragment for a drug carrier and method for the preparation thereof
07/26/2006EP1682552A1 Tocopherol-modified therapeutic drug compounds
07/26/2006EP1682491A1 Non-symmetrical gelling agent
07/26/2006EP1682186A2 Hyperbranched polymer conjugates via non-enzymatic cleavable linker
07/26/2006EP1682185A2 Compositions and methods for treating a posterior segment of an eye
07/26/2006EP1682184A1 Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
07/26/2006EP1682165A1 Use of interferon-tau in medicine
07/26/2006EP1682124A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
07/26/2006EP1682119A1 Discodermolide compositions
07/26/2006EP1682113A1 Inhibitor imaging agents
07/26/2006EP1682094A2 Multilayer dosage form comprising a matrix that influences release of a modulatory substance
07/26/2006EP1682092A2 Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer
07/26/2006EP1682087A1 Chewable tablet
07/26/2006EP1682060A1 Enhancing transdermal administration of hydrophilic drugs
07/26/2006EP1682012A2 Composition and apparatus for transdermal delivery
07/26/2006EP1503747B1 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
07/26/2006EP1501534B1 Desmopressin in an orodispersible dosage form
07/26/2006EP1387703B1 Fibrin material and method for producing and using the same
07/26/2006EP1383539B1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof
07/26/2006EP1349578B1 Medicinal association of a biguanine (metformin) and arginine
07/26/2006EP1257297B1 Compositions and methods for treatemnt of angiogenesis in pathological lesions
07/26/2006EP1242067B1 Calcium formate as a dietary supplement
07/26/2006EP1231933B1 An aqueous solution formulation of alpha-interferon
07/26/2006EP1216025B1 Dispersion formulations containing lipase inhibitors
07/26/2006EP0958812B1 Spherical particle groups, process for preparing the same and spherical particulate pharmaceuticals using the same
07/26/2006EP0904100B1 Cationic lipid and receptor ligand-facilitated delivery of biologically active molecules
07/26/2006EP0835136B1 Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
07/26/2006EP0788346B1 Emulsified drug delivery systems
07/26/2006CN1809607A Drug delivery device comprising an active compound and method for releasing an active compound from a drug delivery device
07/26/2006CN1809594A Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
07/26/2006CN1809584A Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof
07/26/2006CN1809385A Peg-wortmannin conjugates
07/26/2006CN1809384A Chemical combination and method for increasing delivery of coenzyme Q 10
07/26/2006CN1809378A Methods for inhibiting viral replication in vivo
07/26/2006CN1809377A Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
07/26/2006CN1809376A Liquid stabilized protein formulations in coated pharmaceutical containers
07/26/2006CN1809363A Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase
07/26/2006CN1809343A Fast dissolving orally consumable films containing a sucralose as a sweetener
07/26/2006CN1807484A Preparation method of glycosyl teminated functionalized polycaprolactone with different branch structure
07/26/2006CN1806850A Transdermal drug delivery intensifier composition and its application in externally applied medicine
07/26/2006CN1806653A Method for preparing immune polysaccharide and yeast extract by utilizing beer yeast dregs for feeding
07/26/2006CN1266096C Azeotrope-like compositions of tetrafluoroethane, pentafluoropropane and water
07/26/2006CN1265840C Immunity coupler of containing monoclonal antibody Fab' segment of anti TV type collagenase poly glutamic acid-blemycin A5
07/26/2006CN1265839C Glycoconjugates obtained from i(candide Utilis) cells and i(Ricinus)i(communis) seeds
07/26/2006CN1265838C Injectable veterinary composition for small animals
07/26/2006CN1265790C Anti-fungal remedy formulation for external application
07/26/2006CN1265787C Liver-targeting mitomycin magnetic nano-particle and its preparation and application in medicine preparation
07/26/2006CN1265784C Percutaneous administration preparations
07/25/2006US7081518 For the diagnosis and therapy of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin
07/25/2006US7081495 Cationic compounds and their use as macro molecular carriers
07/25/2006US7081445 Cyclosporin galenic forms
07/25/2006US7081354 Interleukin and albumin fusion protein
07/25/2006US7081255 Antifungal compositions with improved bioavailability
07/25/2006US7081254 For relieving or improving skin roughness and suppressing wrinkling, shows neither any offensive smell nor stickiness, gives users a dry feel upon use, and exhibits controlled foaming upon production and stability
07/25/2006US7081252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
07/25/2006US7081251 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml
07/25/2006US7081250 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml
07/25/2006US7081249 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
07/25/2006US7081246 Stable hydroalcoholic compositions